Bayer will reduce internal R & D work on drugs, eliminating hundreds of researchers while turning to its partners to unveil plan to cut 12,000 jobs – Endpoints News

Bayer is pursuing plans to restructure its R & D activity in the field of medicines and is removing 900 people in the research sector as part of a broad plan to reduce the total number of drugs by 12,000. employees as part of a global overhaul.

The details of the changes in R & D – a rumor that has been circulating for months – are slim, without knowing which projects are under threat. According to their statement, 900 jobs are being researched and developed in the pharmaceutical sector, while another 350 are being cut in a German Factor VIII factory. The focus will now be on drug R & D, reducing internal work while involving external partners to take on more of the burden.

In their statement, the German pharmaceutical company said that its research and development measures "include the accelerated development of the innovation model and a restructuring of internal research and development activities. The resources released by the reduction of internal capacities must be directed towards the reinforcement of the investments in the models of collaborative research and the external innovations. "

Bayer also plans to sell consumer products and withdraw from the animal health sector as a result of the Monsanto acquisition, which faces its own internal cuts as a storm of lawsuits would besiege the new owners.

While Roche is upsetting the hemophilia market with its new drug Hemlibra, Bayer announces that it will close the "Factor VIII facility built in Wuppertal, Germany, and … will concentrate all factor production." Recombinant VIII at Berkeley, CA.

Rumors about a major upheaval in R & D have been circulating for the most part in 2018. Wirtschaftswoche started at the end of May, indicating that the possible reductions could reach 1,000 people in the reorganization. Reuters then announced that job cuts and relocations were being explored as the German pharmaceutical group sought to raise more money to acquire new licensed therapies for its pipeline.